Thomas Lynch Sells 20,000 Shares of Billiontoone (NASDAQ:BLLN) Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Thomas Lynch sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $99.99, for a total transaction of $1,999,800.00. Following the transaction, the insider directly owned 700 shares of the company’s stock, valued at $69,993. This trade represents a 96.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Stock Performance

NASDAQ:BLLN opened at $98.77 on Friday. The company has a market cap of $4.66 billion and a P/E ratio of 141.10. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17. The firm’s 50 day moving average is $111.64 and its two-hundred day moving average is $95.81. Billiontoone, Inc. has a fifty-two week low of $61.96 and a fifty-two week high of $150.44.

Billiontoone (NASDAQ:BLLN) last issued its earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share for the quarter, hitting the consensus estimate of $0.15. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%.The business had revenue of $109.45 million for the quarter. Analysts expect that Billiontoone, Inc. will post 0.83 EPS for the current year.

Wall Street Analysts Forecast Growth

BLLN has been the topic of several research analyst reports. JPMorgan Chase & Co. reduced their price objective on Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research note on Thursday, August 6th. BTIG Research cut their price target on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Guggenheim began coverage on shares of Billiontoone in a research report on Monday, June 29th. They set a “buy” rating and a $125.00 price target on the stock. Zacks Research cut shares of Billiontoone from a “hold” rating to a “strong sell” rating in a research report on Monday, August 31st. Finally, Canaccord Genuity Group initiated coverage on shares of Billiontoone in a research report on Wednesday, September 2nd. They issued a “buy” rating and a $120.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $125.88.

Institutional Investors Weigh In On Billiontoone

Institutional investors and hedge funds have recently modified their holdings of the stock. Rossby Financial LCC purchased a new stake in shares of Billiontoone during the 4th quarter valued at about $25,000. Integrated Wealth Concepts LLC purchased a new position in Billiontoone in the 2nd quarter worth approximately $29,000. MCF Advisors LLC boosted its holdings in Billiontoone by 330.8% in the 2nd quarter. MCF Advisors LLC now owns 448 shares of the company’s stock worth $54,000 after acquiring an additional 344 shares during the period. Wells Fargo & Company MN acquired a new stake in Billiontoone in the fourth quarter valued at approximately $76,000. Finally, Smartleaf Asset Management LLC purchased a new stake in shares of Billiontoone during the fourth quarter valued at approximately $80,000.

Billiontoone Company Profile

BillionToOne, Inc is a molecular diagnostics company that develops blood-based tests designed to provide genetic and health information from small amounts of biological material. The company’s technology uses its proprietary quantitative counting template approach to improve the accuracy and sensitivity of molecular testing.

The company’s primary offerings include UNITY, a portfolio of prenatal genetic tests. These services support screening for chromosomal conditions, single-gene disorders and carrier status, and are designed to help healthcare providers assess fetal and maternal genetic risks using a maternal blood sample.